These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31427687)

  • 1. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer.
    Narita S; Nomura K; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nagashima K; Habuchi T
    Sci Rep; 2019 Aug; 9(1):12071. PubMed ID: 31427687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer.
    Sato H; Narita S; Tsuchiya N; Koizumi A; Nara T; Kanda S; Numakura K; Tsuruta H; Maeno A; Saito M; Inoue T; Satoh S; Nomura K; Habuchi T
    BMC Urol; 2018 May; 18(1):32. PubMed ID: 29739368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.
    Parikh M; Tangen C; Hussain MHA; Gupta S; Callis S; Jo Y; Harzstark A; Paller CJ; George S; Zibelman MR; Cheng HH; Maughan BL; Zhang J; Pachynski RK; Bryce AH; Lin DW; Quinn DI; Lerner SP; Thompson IM; Dorff TB; Lara PN; Agarwal N
    Eur Urol Oncol; 2024 Oct; 7(5):1097-1104. PubMed ID: 38523017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With
    Kobayashi T; Namitome R; Hirata YU; Shiota M; Imada K; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2019 Jun; 39(6):3191-3195. PubMed ID: 31177166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
    Wang Y; Xu F; Pan J; Zhu Y; Shao X; Sha J; Wang Z; Cai Y; Liu Q; Dong B; Xue W; Huang Y
    BMC Cancer; 2016 May; 16():329. PubMed ID: 27222030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
    Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
    Sonpavde G; Pond GR; Berry WR; de Wit R; Armstrong AJ; Eisenberger MA; Tannock IF
    Urol Oncol; 2012 Sep; 30(5):607-13. PubMed ID: 20888271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
    Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
    World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer.
    Ebbinge M; Berglund A; Varenhorst E; Hedlund PO; Sandblom G;
    BJU Int; 2018 Oct; 122(4):583-591. PubMed ID: 29611275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
    Narita S; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Koizumi A; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nomura K; Habuchi T
    Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
    Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
    Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
    Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.
    López-Torrecilla J; Boladeras A; Cabeza MA; Zapatero A; Jove J; Esteban LM; Henriquez I; Casaña M; González-San Segundo C; Gómez-Caamaño A; Mengual JL; Hervás A; Muñoz JL; Sanz G
    Strahlenther Onkol; 2015 Oct; 191(10):792-800. PubMed ID: 26156249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
    Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.
    Hahn NM; Yiannoutsos CT; Kirkpatrick K; Sharma J; Sweeney CJ
    Clin Genitourin Cancer; 2014 Feb; 12(1):33-40.e4. PubMed ID: 24126237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.